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ABSTRACT 
Wnt/β-catenin and PI3K/AKT pathways play a central role in cancer. We describe the function of 
their corresponding transcriptional effectors — β-catenin and FOXO3a — in colon cancer 
progression. Their simultaneous nuclear accumulation and activation promotes cell scattering and 
metastasis, by regulating a defined set of target genes. Unexpectedly, the anti-tumoral AKT 
inhibitor API-2 promotes nuclear FOXO3a accumulation and metastasis of cells with high nuclear 
β-catenin. β-catenin confers resistance to FOXO3a-mediated apoptosis induced by PI3K and 
AKT inhibitors in patient-derived primary cultures and in corresponding xenograft tumors in mice. 
This resistance is reverted by Wnt/β-catenin signaling inhibitor XAV-939. FOXO3a does not 
behave as a tumor suppressor but rather as a metastasis inductor activated by PI3K or AKT 
inhibitory drugs when acting in concert with β-catenin. We show that it is possible to evaluate β-
catenin status and the response of patient-derived cells to these target-directed drugs before 
deciding on treatment. We also consider that this evaluation could be essential to the provision of 
a safer and more effective personalized treatment. 
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INTRODUCTION 
Colon cancer is a leading cause of death worldwide1. Although surgical resection combined 
with adjuvant therapy is efficient at early stages of the disease, subsequent relapse and 
metastasis are frequent. At these advanced stages, conventional therapies are ineffective 1-3. It is 
important to identify novel predictive biomarkers and to provide tools to facilitate treatment 
decisions. A better understanding of the molecular mechanisms responsible for drug-resistance 
and metastasis is crucial to these aims.  
Abnormal activation of the Wnt/β-catenin pathway by mutations in Adenomatous Polyposis 
Coli (APC), AXIN2 or β-catenin (CTNNB1) is responsible for the initiation of almost all colon 
cancers4,5. Wnt signal leads to the disassembly of a destruction complex formed by APC, AXIN 
and GSK3beta. This complex can no longer target β-catenin for degradation. As a result, β-
catenin accumulates in the cell, enters the nucleus, binds the TCF/LEF transcription factors and 
induces expression of Wnt target genes6. A significant number of these genes play key roles in 
tumour progression by inducing cell proliferation, while fewer genes drive cell motility and 
migration7,8.  
The pleiotropic effects of the Wnt pathway are, however, so broad and varied that they 
cannot be explained through this molecular mechanism alone. We and others have reported that 
binding of β-catenin to different transcription factors enhances the expression of alternative sets 
of target genes directing cell-fate during development, tissue homeostasis and cancer9-13. 
FOXO3a is one of these transcription factors, for which β-catenin acts as a transcriptional 
coactivator, enhancing the expression of genes involved in longevity and oxidative stress14. 
However, to our knowledge the possible physiological relevance of the crosstalk between 
FOXO3a and β-catenin in cancer has not been addressed. 
FOXO proteins control multiple processes in eukaryotic organisms by regulating the 
expression of specific sets of genes involved in stem-cell maintenance, stress resistance, 
longevity, differentiation, metabolism or tumor suppression15-19. In cancer, FOXO transcription 
factors are considered tumor suppressors because they induce cell-cycle arrest and 
apoptosis16,20-23. However, prolonged activation of FOXO proteins confers drug-resistance in 
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cancer cells by promoting the expression of genes responsible for antioxidant defence, DNA 
repair or drug efflux20,22. The molecular mechanisms underlying such dual activity, cell death 
versus resistance, have not yet been characterized.  
The response of FOXO proteins to environmental stimuli is controlled by their subcellular 
localization16. Phosphorylation of FOXO proteins by activated AKT or SGK1 at three specific 
residues induces their sequestration in the cytoplasm and the consequent inhibition of their 
capacity to regulate target genes24,25. AKT is part of the RAS/PI3K/PTEN/AKT/mTOR oncogenic 
pathway, which is frequently altered by activating mutations in colon cancer and many others26. In 
this scenario, FOXO proteins are retained in the cytoplasm of cancer cells, which blocks their 
tumor suppressor activity20. Concerted efforts have been made in both academia and industry to 
identify specific PI3K or AKT inhibitors with which to fight cancer20,27-30. The aim is to relocate 
FOXO proteins back into the nucleus and thus restore their capacity to induce cell-cycle arrest 
and apoptosis20. The anti-tumoral efficacy of some of these compounds has been tested in 
clinical trials, with promising results27,28. In this study we used the PI3K inhibitor NVP-BKM120 
and the AKT signaling inhibitor-2 (API-2), also known as Triciribine Phosphate Monohydrate 
(TCN-PM, VD-0002). Both drugs inhibit cell growth and induce apoptosis in human cancer cells in 
culture and in tumors growing in mice31,32. Phase I and II clinical trials with NVP-BKM120 and 
API-2 respectively have been conducted in patients with solid metastatic cancers33-35. 
Considering the role of Wnt/β-catenin and PI3K/AKT pathways in tumorigenesis and the 
interaction of their corresponding transcriptional effectors, FOXO3a and β-catenin, we decided to 
study their crosstalk in colon cancer. Unexpectedly, we found that their joint action induced 
metastasis and that β-catenin conferred resistance to FOXO-induced apoptosis. PI3K and AKT 
inhibitors not only failed to induce apoptosis in vitro and in vivo, but they also promoted 
metastasis when the concentration of nuclear β-catenin was high in colon-cancer cells. By 
studying the response of patient-derived colon cancer initiating cells to such target-directed drugs 
we highlight the clinical relevance of our findings. 
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Our results indicate that drugs promoting FOXO tumor suppressor activity can induce metastasis 
acting in concert with nuclear β-catenin, by inducing a set of common target genes. We show that 
it is possible to monitor β-catenin levels and drug response in patient-derived cell cultures. We 
also consider this evaluation to be advisable for the provision of a safer and more effective 
individual treatment. Those patients with high nuclear β-catenin levels are not expected to benefit 
from PI3K or AKT inhibitory drugs, but they may do so through the simultaneous inhibition of 
Wnt/β-catenin signaling.  
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RESULTS 
High nuclear FOXO3a and β-catenin levels correlate with metastatic tumor stages and 
shorter survival in colon-cancer patients.  
We analyzed the expression of FOXO3a and β-catenin in series of patients´ carcinomas at 
different stages of colon-cancer progression. Nuclear FOXO3a accumulated alone in non-
malignant adenomas but always colocalized with β-catenin in the nucleus of tumoral cells in 
carcinomas or liver metastasis (Fig. 1a-e and Supplementary Fig. 1c). Such colocalization was 
revealed by plotting the values of nuclear signal for FOXO3a and β-catenin colocalization against 
that for nuclear FOXO3a alone (Fig. 1d). We also detected carcinomas with high nuclear β-
catenin but low nuclear FOXO3a signal (Supplementary Fig. 1a,b). The highest nuclear levels of 
both factors were observed in a subset of primary carcinomas at stages III and IV from patients 
with metastatic disease (Fig. 1e). Patients with high nuclear FOXO3a and β-catenin colocalization 
signal presented on average eight months shorter survival. Median survival was 33.7 months for 
low and 25.7 months for high FOXO3a and β-catenin content (HR, 1.724; 95% CI, 1.164-2.552) 
(Fig. 1f). Those patients presenting the 10% highest colocalization signal did not survive longer 
than 28 months, whereas at this time point the remaining patients presented 50% survival. In this 
case median survival was 28.9 months for low and 21.03 months for high FOXO3a and β-catenin 
content (HR, 6.392; 95% CI, 2.322-17.6) (Fig. 1g,h). Nuclear FOXO3a on its own also correlated 
with metastatic stages (Supplementary Fig.1c) and shorter median survival (Low = 32.57 vs High 
= 25.37 months. HR, 1.684; 95% CI, 1.137-2.493) (Supplementary Fig. 1e). In contrast, β-catenin 
signal alone did not predict metastasis or survival (HR, 1.212; 95% CI, 0.8331-1.765) 
(Supplementary Fig. 1d,f). 
 
β-catenin cooperates with FOXO3a to promote cell scattering and metastasis, conferring 
resistance to FOXO3a-induced apoptosis. 
To study the effect of both transcription factors in colon cancer cells we expressed a 
tamoxifen-inducible (4OHT) AKT-insensitive mutant of FOXO3a (FOXO3a3A-ERTM)36 and a 
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stable β-cateninS33Y inducible by doxycycline (DOX) in DLD1 cells (clone: DLD1Fβ-C7). Both 
proteins accumulated in the nucleus following treatment, reaching nuclear levels comparable to 
those caused by H2O2 (FOXO3a) or present in cancer cell lines such as HCT116 or SW480 with 
naturally-occurring β-catenin accumulation (Fig. 2a and Supplementary Fig. 2a-d). 4OHT induced 
the known FOXO3a target gene CDKN1A (p21CIP1) and its protein levels (Fig. 2b,c)37. Likewise, 
DOX induced the TCF/β-catenin target gene LEF1, whose expression was reduced by 4OHT 
(FOXO3a) (Fig. 2b,c)38. Simultaneously, nuclear β-catenin accumulation enhanced the capacity 
of FOXO3a to induce CDKN1A gene and protein expression (Fig. 2b,c).  
As expected39, exogenous FOXO3a reduced proliferation accumulating DLD1Fβ-C7 cells in 
G1-phase of the cell cycle. In contrast, β-catenin promoted proliferation, although the FOXO3a 
effect was dominant (Fig. 2d and Supplementary Fig. 3a,b). Surprisingly, β-catenin completely 
rescued DLD1Fβ-C7 cells from FOXO3a-induced apoptosis (Fig. 2e). Such apoptosis induction 
and rescue was independent of proliferation since it was preserved in cells arrested in G1 phase 
upon Mitomycin C pre-treatment (Supplementary Figure 3c-e). These results were confirmed in 
vivo by subcutaneous injection to nude mice of a pool of DLD1Fβ cells that were all positive for 
FOXO3a3A-ER, although only 62% of them expressed β-cateninS33Y-IRES-eGFP (Supplementary 
Fig. 4a,c,d and Supplementary Fig. 5a,b). This mixed pool of cells recapitulated similar 
heterogeneity in nuclear β-catenin levels to that detected in human colon carcinomas 
(Supplementary Fig. 4b). Tumors thus grew more rapidly in mice treated with DOX but much 
more slowly in mice treated with 4OHT compared to controls (Vehicle) (Fig. 2f). Nuclear FOXO3a 
accumulation was again dominant over β-catenin activity, and the combined treatment (4OHT + 
DOX) resulted in tumors with similar size at the end of the experiment to those treated with 4OHT 
alone. Curiously, tumors with nuclear FOXO3a and β-catenin (4OHT + DOX) grew faster at the 
beginning of the experiment than 4OHT-treated tumors, probably due to the protective effect of β-
catenin against an accumulative FOXO3a-induced apoptosis (Fig. 2f). This result reflects that β-
catenin dominates the balance between apoptosis and proliferation over FOXO3a in the context 
of long-term tumor growth. We again observed that FOXO3a induced apoptosis in DLD1Fβ cells 
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but only in the population lacking β-catenin expression (eGFP-negative cells) both in culture 
(Supplementary Fig. 4e) and in xenograft tumors (Fig. 2g). Within the tumor tissue this resulted in 
massive FOXO3a-induced cell death, which was partially rescued upon β-catenin expression 
(Supplementary Fig. 5c,d). Detailed histological analysis and quantification showed that nuclear 
accumulation of FOXO3a and β-catenin was significantly increased upon 4OHT or DOX 
treatment respectively (P < 0.0001), although some heterogeneity was observed across tumor 
tissues (Supplementary Fig. 5f,e). 
Cells accumulating high levels of both transcriptional regulators lost their epithelial 
phenotype in subconfluent cell cultures and in vivo (Fig. 2a, Supplementary Fig. 5f and 
Supplementary Fig. 6a,b). Since human primary tumors with high FOXO3a and β-catenin 
colocalization signal corresponded to patients with local or distant metastasis (Stage III or IV; Fig. 
1e), this cell scattering phenotype may reflect a more motile or invasive capacity — both of which 
are necessary for cancer cells to acquire metastatic potential. FOXO3a accumulation alone 
initiated a rapid loss of the epithelial phenotype that preceded cell death by apoptosis (Fig. 2a,e 
and Supplementary Fig. 6a). 
We detected relocation of E-cadherin protein from cell-to-cell contacts to cytoplasmic 
aggregates (Fig. 3a,b and Supplementary Fig. 6e,f) in cells in which the joint action of FOXO3a 
and β-catenin induced this scattering phenotype (Supplementary Fig. 6a,b). E-cadherin protein 
fragments were not detected, which ruled out E-cadherin proteolysis as a mechanism of cell-to-
cell detachment (Supplementary Fig. 6c). Furthermore, E-cadherin expression was not repressed 
and Snail1, Zeb1 or Slug levels did not increase (Supplementary Fig. 6c,d), which also ruled out 
canonical epithelial-to-mesenchymal transition (EMT). Further, these morphological changes 
correlated with increased cell motility and adhesion to substrate (Fig. 3c,d and Supplementary 
Fig. 6g). Although a small proportion of cells acquired increased size and an extended cytoplasm 
resembling the morphology of senescent cells, they were negative for Senescence-Associated β-
galactosidase activity (Fig. 2a and Supplementary Fig. 6b,h). In contrast, such cell shape was 
accompanied by an actin organization typical of lamellipodia (Supplementary Fig. 6f), a cellular 
structure associated with high cell motility (Fig. 3c). 
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We then assessed the metastatic potential of this phenotype induced by FOXO3a and β-
catenin nuclear activity by injecting cells into the cecum wall of immunodeficient mice. Since 
DLD1Fβ cells had limited capacity to initiate tumors in the cecum, we established a different 
HT29 colon cancer cell line with the same inducible systems to express exogenous FOXO3a and 
β-catenin (HT29Fβ). We used a pool of these cells, all of which expressed FOXO3a3A-ER and a 
constitutive Luciferase reporter, but only 41% of which contained the β-cateninS33Y-IRES-eGFP 
construct (Supplementary Fig. 7a,b). As in the case of DLD1Fβ cells, DOX induced proliferation, 
protected from FOXO3a-induced apoptosis and over time enriched the β-catenin-expressing cell 
population (Supplementary Fig. 7c-e). Again, FOXO3a inhibition of proliferation was dominant 
(Supplementary Fig. 7d), and the activity of both transcriptional regulators induced cell scattering 
(Supplementary Fig. 7f). To examine their metastatic potential we injected these HT29Fβ cells 
into the cecum wall of nude mice and induced nuclear accumulation of FOXO3a and/or β-catenin 
by treating the mice with 4OHT, DOX or both. First, using bioluminescent live-imaging 
techniques, we observed an increase in tumor signal in DOX-treated animals, whereas the signal 
gradually decreased or even disappeared in a subset of mice treated with 4OHT (6 out of 11). 
Most of the mice treated with both drugs showed a weak tumor signal (Supplementary Fig. 8a,b).  
As the luciferase signal from large primary tumors masked that from metastases in a subset 
of mice, we performed detailed necropsies and ex vivo analyses of internal organs by 
luminometry to improve metastases detection. Positive tissues were analyzed by histology to 
confirm metastases (Fig. 3f and Supplementary Fig. 8c). The combined nuclear accumulation of 
FOXO3a and β-catenin significantly increased the number of mice harboring metastases (P = 
0.022), the lungs being the most frequent dissemination site (P = 0.038). Peritoneal 
carcinomatosis (P = 0.07) and infiltrated lymph nodes (P = 0.157) also showed a tendency to 
harbour more metastases (Fig. 3e-g). A control experiment conducted with parental luciferase-
expressing HT29 cells failed to reveal such differences (Supplementary Fig. 8d). 
Immunohistological analysis confirmed nuclear FOXO3a accumulation in vivo following 4OHT 
treatment. This led to dramatic intra-tumoral cell death, which was rescued by β-catenin 
(Supplementary Fig. 9a,b).  
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As observed in DLD1Fβ cells, E-cadherin relocation, loss of epithelial organization and cell 
scattering again occurred only in the eGFP-β-cateninS33Y-positive cell population, in tumors 
growing in mice treated with both 4OHT and DOX (Supplementary Fig. 9c,d). Such cell scattering 
or tumor budding, which is a histopathological feature indicative of metastasis and poor 
prognosis41,42, was significantly increased in primary tumors growing in the cecum wall of mice 
treated with 4OHT + DOX (Fig. 3g,h). Nuclear FOXO3a and β-catenin colocalization was also 
found in scattered cells at the invasive front of human colon carcinomas (Supplementary Fig. 3i, 
j). By measuring FOXO3a and β-catenin colocalization signal in the tumor bulk, we observed its 
positive correlation with tumor budding at the invasive front. (Fig. 3i,j,k). For most of the primary 
human carcinomas analyzed, both factors presented similar nuclear levels in the tumor bulk and 
in the invasive front. Only a minor proportion showed increased accumulation of these factors at 
the invasive front as previously described for β-catenin (Supplementary Fig. 10b,d)43, although 
this difference was not statistically significant in our cohort of patients (Supplementary Fig. 
10a,c,d).  
 
FOXO3a and β-catenin regulate a set of target genes involved in metastasis. 
FOXO3a and β-catenin regulate the expression of target genes that commit cells to specific 
phenotypes. We therefore assumed that most of their combined activity inducing metastasis 
would be exerted through the regulation of a common set of target genes. Transcriptomic 
analyses in DLD1Fβ-C7 cells were performed to define the gene expression profile attributable to 
either FOXO3a, β-catenin, or both in combination. Similar to a previous report44, FOXO3a alone 
completely transformed the gene expression pattern in DLD1Fβ cells. In contrast, β-catenin alone 
produced only minor changes. However, β-catenin co-expression diverted FOXO3a-regulated 
genes to a different expression profile (Fig. 4a,b, Supplementary Table 1 and 2). In general, β-
catenin enhanced the expression of known or novel FOXO3a target genes (Fig. 4c and 
Supplementary Fig. 11a,b and Supplementary Table 1 and 2). In contrast to these induced 
genes, others involved in cell differentiation such as MUC13, VIL1 or CDX2 were repressed by 
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nuclear FOXO3a, and concomitant β-catenin further enhanced such inhibition (Supplementary 
Fig. 11b).  
β-catenin enhances the expression of many FOXO3a target genes involved in cytoskeleton 
remodeling, cell shape and motility (Supplementary Table 3). The products of some of these 
genes form part of the same protein complexes that control the stability of cell-to-cell contacts. 
This is the case of the ARHGAP17-RICH1/MPP5-PALS/CD2AP complex, which controls tight 
junctions by modulating the activity of the small GTPase Cdc42 on actin cytoskeleton45. Some 
components of tight junctions like ZO1 or Claudins 1, 10 and 16 are also regulated 
(Supplementary Fig. 11c,d). Other factors, like IQGAP2, ANK3 or CAV1, which control the 
stability of adherens junctions and E-cadherin localization, are also simultaneously regulated by 
FOXO3a and β-catenin (Supplementary Fig. 11c,d).  
We observed E-cadherin relocation from cell-to-cell contacts to cytoplasmic aggregates (Fig. 
3a,b and Supplementary Fig.6e,f and Supplementary Fig. 9d), a process that is regulated by 
IQGAP proteins that induce disassembly of adherens junctions and cell scattering46-48. Therefore, 
we selected this FOXO3a/β-catenin target gene to evaluate its relevance as an effector of the 
observed changes in cell phenotype. We interfered with the expression of IQGAP2 protein, 
induced by FOXO3a and β-catenin in DLD1Fβ-C7 cells, using eight different specific lentiviral 
shRNAi constructs, separately or as a viral pool (Supplementary Fig. 12a,b and Supplementary 
Table 8b). IQGAP2 knock down partially preserved the amount of E-cadherin associated with the 
actin cortex at cell-to-cell contacts in DLD1Fβ-C7 cells treated with 4OHT + DOX (Supplementary 
Fig. 12c,d). Besides, the induction of cell motility promoted by nuclear FOXO3a and β-catenin, 
was also significantly reduced when IQGAP2 was knocked down in DLD1Fβ-C7 cells 
(Supplementary Fig. 12e). Nevertheless, the reduction of IQGAP2 still allowed a significant 
increase in E-cadherin relocation and in cell motility of DLD1Fβ-C7 cells upon 4OHT + DOX 
treatment. Finally, we observed that IQGAP2 expression correlated with tumor budding in a set of 
59 human colon carcinomas (Supplementary Fig. 12f).  
IQGAP2 was observed in association with E-cadherin aggregates in the cytoplasm and 
alone in the nucleus of scattering DLD1Fβ cells (Supplementary Fig. 13a,b). Human colon 
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carcinomas also presented punctuate accumulation of E-cadherin and IQGAP2 protein 
complexes in the cytoplasm of cancer cells with disrupted epithelial organization (Supplementary 
Fig. 13c,d). Likewise, subcutaneous tumors from DLD1Fβ cells presented increased expression 
of IQGAP2 in cells that accumulated FOXO3a and β-catenin upon simultaneous 4OHT and DOX 
treatment (Supplementary Fig. 13e). 
FOXO3a and β-catenin regulated a defined set of metastasis-relevant genes – some 
synergistically and some additively (Fig. 4d,e, Supplementary Table 4). In addition to IQGAP2, we 
also studied CYR61 and CLDN1, which had been reported to be associated with cell-to-cell 
disassembly, cell scattering, motility and metastasis (Fig. 4f,g Supplementary Fig. 14)47-50. 
Furthermore, the levels of nuclear FOXO3a alone or FOXO3a and β-catenin colocalization signal 
correlated with the amount of each of these three target genes in a set of 59 primary human colon 
carcinomas (Fig. 4h and Supplementary Fig. 15a,c). β-catenin expression did not show any 
significant correlation (Supplementary Fig. 15b,d). 
Gene set enrichment analysis of microarray data from DLD1Fβ-C7 cells showed that 
FOXO3a regulated genes involved in apoptosis, including known targets like TNFSF10 (TRAIL), 
BCL2L11 (BIM) or FASLG (FAS ligand), whereas its co-expression with nuclear β-catenin 
modulated additional gene sets controlling cell morphology, adhesion and motility 
(Supplementary Fig. 11a-d, Supplementary Fig. 16a-c and Supplementary Table 3). Consistently 
with the inhibition of FOXO3a-induced apoptosis (Fig. 2e,g), nuclear β-catenin attenuated the up-
regulation of the pro-apoptotic genes TNFSF10 and BCL2L11 while it synergized with FOXO3a to 
induce FASLG, which has pro- as well as anti-apoptotic functions, and the anti-apoptotic gene 
HIPK3 (Supplementary Fig. 11a and 16c). Moreover, β-catenin caused nuclear translocation of 
FAS-associated adaptor protein (FADD) and inhibited PARP1 cleavage induced by FOXO3a 
(Supplementary Fig. 16d,e). 
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The AKT inhibitor API-2 promotes metastasis from colon-cancer cells with high nuclear β-
catenin content. 
We tested the hypothesis that the pharmacological inhibition of AKT and subsequent nuclear 
FOXO3a accumulation promotes metastasis cooperating with β-catenin. To this end, we induced 
FOXO3a accumulation by treating DLD1Fβ cells with the AKT inhibitor API-2. In this context, we 
observed a cell scattering phenotype only when high nuclear β-catenin levels were induced by 
DOX treatment (Supplementary Fig. 17b). Some of the FOXO3a and β-catenin target genes 
defined in our metastasis signature (Fig. 4d,e) were induced by API-2 and further enhanced by β-
catenin in DLD1Fβ-C7 colon cancer cells (Fig. 5a). 
In tumors of HT29Fβ cells growing in the cecum wall of nude mice, API-2 and DOX induced 
nuclear accumulation of FOXO3a and beta-catenin, respectively, as well as the loss of epithelial 
phenotype and the promotion of cell scattering (Fig. 5b and Supplementary Fig.17a). Such 
nuclear accumulation was heterogeneous across tumor regions, reflecting that 41% of injected 
cells were infected with β-catenin-expressing lentiviruses (Supplementary Fig. 7a). 
Most importantly, although API-2 reduced primary tumor bioluminescence signal, it 
simultaneously promoted the development of metastasis when nuclear β-catenin was co-
expressed (Fig. 5c,d). A significantly higher number of mice presented metastases (P = 0.015) 
when treated with API-2 + DOX (Fig. 5d). Mice affected in lungs (P = 0.082), lymph nodes (P = 
0.576) or presenting carcinomatosis (P = 0.15) were more frequent upon double treatment as 
compared with vehicle-treated mice, although the difference was not significant (P < 0.05) (Fig. 
5d). Strikingly, API-2 treatment produced liver metastasis when β-catenin levels were high. This 
dissemination site had not been detected before in our HT29Fβ-cell model and recapitulated the 
main organ affected in human colon-cancer patients (Fig. 5d-f)2,3. 
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β-catenin confers resistance to FOXO3a-induced apoptosis promoted by PI3K and AKT 
inhibitors in patient-derived colon-cancer initiating cells. 
PI3K and AKT inhibitors exert part of their anti-tumoral activity by inducing nuclear FOXO3a 
accumulation and apoptosis (Supplementary Fig. 17b-e)20. Based on our previous data, we tested 
whether β-catenin conferred resistance to PI3K inhibitors LY-249002 and NVP-BKM120 or to the 
AKT inhibitor API-2. We observed a dose-dependent resistance to API-2-induced apoptosis 
correlating with nuclear β-catenin content in DLD1Fβ-C7 cells (Supplementary Fig. 17f-h). 
HCT116F cells with high endogenous amounts of mutant nuclear β-catenin or HT29Fβ cells with 
medium levels were more resistant to NVP-BKM120 and API-2-induced apoptosis than DLD1Fβ 
cells (Supplementary Fig. 18a,b and Supplementary Table 5). In L8 colon cancer cells that are 
heterogeneous respective to nuclear β-catenin levels and transcriptional activity, LY-249002 
preferentially induced apoptosis in the low β-catenin expressing cell population (Supplementary 
Fig. 19a-c). Remarkably, the tankyrase inhibitor XAV-939, which reduces nuclear β-catenin levels 
and transcriptional activity (Supplementary Fig. 17d,e and Supplementary Fig. 19d-f)51, increased 
the sensitivity of HCT116F cells to NVP-BKM120- and API-2-induced apoptosis (Supplementary 
Fig. 18b). 
Next, we applied our findings to sphere cultures of patient-derived colon cancer cells 
(Supplementary Fig. 18f). Our primary cultures regenerate carcinomas that are histologically 
indistinguishable from patients’ primary tumors upon subcutaneous injection in NOD-SCID mice 
(Fig. 6a and Supplementary Fig. 18c). Since our sphere cultures demonstrated such self-renewal 
capacity and pluripotency, they are assumed to contain colon-cancer stem cells. They also 
recapitulated the original levels of nuclear β-catenin in xenograft tumors (Fig. 6b and 
Supplementary Fig. 18d). Treatment of sphere cultures with LY-294002 or NVP-BKM120 and 
API-2 induced nuclear accumulation of FOXO3a and apoptosis in cells derived from patients T61, 
T68, T70 and T86, who originally presented low nuclear β-catenin levels in their primary 
carcinomas. In contrast, sphere cultures derived from patients T49 and T59 with high nuclear β-
catenin were innately resistant to cell death mediated by LY-249002 and NVP-BKM120 or API-2, 
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respectively. Importantly, reduction of β-catenin levels with XAV-939 reverted such resistance 
(Fig. 6b-d and Supplementary Fig. 18d,e,g). In contrast, sphere cultures were resistant to 
conventional chemotherapeutic agents like 5-FU or Oxaliplatin, and their combination with XAV-
939 did not sensitize them to apoptosis (Supplementary Fig. 18h). 
We observed similar results in vivo. Thus, API-2 inhibited growth of subcutaneous tumors 
generated in NOD-SCID mice when injecting cells derived from patient T61 (low β-catenin), 
whereas those from patient T70 (intermediate β-catenin) presented partial response and those 
from patient T49 (high β-catenin) were resistant (Fig. 6d,e). Analysis of patient-derived xenograft 
tumor T49 revealed that API-2 treatment induced nuclear FOXO3a accumulation and increased 
cytoplasmatic IQGAP2 in tumor cell populations with disrupted epithelial organization (Fig. 6f,g). 
We also observed an enrichment of cells with high nuclear β-catenin levels in API-2-treated 
xenograft tumors from patients T49 compared to controls (vehicle; Fig. 6f,g). The reduction of S6 
ribosomal protein phosphorylation confirmed the efficacy of API-2 treatment in inhibiting 
PI3K/AKT pathway signaling in vivo (Supplementary Fig. 20a,b). 
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DISCUSSION 
Metastases are responsible for over 90% of deaths in cancer patients. However, the 
molecular mechanisms that drive cancer cells towards metastasis are poorly understood. Our 
data reveal novel mechanisms by which crosstalk between Wnt/β-catenin and PI3K/AKT/FOXO 
oncogenic pathways promotes metastasis in colon cancer. 
These two pathways interact at different levels. AKT phosphorylates GSK3β52 inhibiting its 
capacity to phosphorylate β-catenin and commit it to proteasomal degradation. Therefore, AKT 
activation leads to β-catenin stability and transcriptional activation in some cell contexts. 
Furthermore, SGK1 is a TCF/LEF-β-catenin target gene that encodes a kinase that 
phosphorylates FOXO3a and prevents its accumulation in the nucleus25. Wnt/β-catenin pathway 
therefore inhibits FOXO3a transcriptional activity and induces apoptosis by increasing SGK1 
activity in cancer cells. In addition, oxidative stress induces FOXO3a nuclear accumulation 
through its direct phosphorylation by activated JNK15,53. All these upstream signals may 
determine the nuclear amounts of FOXO3a and β-catenin in human carcinomas. However, since 
in our experiments we used mutant forms of FOXO3a and β-catenin that cannot be 
phosphorylated by SGK1 or AKT and GSK3β, respectively, we conclude that both transcription 
factors can induce the metastasis and drug-resistant phenotypes by themselves, independently of 
the main upstream signals that normally control their nuclear accumulation.  
Although it has been demonstrated that abnormal activation of the Wnt/β-catenin pathway is 
responsible for colon cancer initiation, less evidence supports its role in metastasis54. Wnt signal 
may participate by inducing TCF/LEF-β-catenin target genes involved in cancer cell migration and 
invasion like metalloproteases, urokinases or transcriptional repressors55-58.  
The contribution of the PI3K/AKT/FOXO signaling to metastasis is controversial. On the one 
hand, some studies demonstrate that mutational activation of PI3K and induction of AKT activity 
mediate metastasis59, encouraging the use of therapeutic PI3K and AKT inhibitors. On the other 
hand, AKT can inhibit cell motility by blocking NFAT transcriptional activity60. Our results, which 
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show that AKT inhibitors promote metastasis by nuclear FOXO3a accumulation and cooperation 
with β-catenin in colon cancer, support the second notion. 
Few studies correlate FOXO3a function with metastasis or poor prognosis in cancer61,62. On 
the contrary, most studies define FOXO proteins as tumor suppressors, since they induce cell-
cycle arrest and apoptosis15,20-23. Indeed, the combined knock-down of FOXO1, 3, and 4 in mice 
is responsible for tumor initiation63. However, our results reveal a novel and unexpected role of 
FOXO3a as an inducer of metastasis when acting in concert with β-catenin. Importantly, we 
observed that their simultaneous nuclear accumulation in primary tumors correlated with Stages 
III and IV with local or distant metastases and significantly shorter overall survival of colon-cancer 
patients. 
Loss of a differentiated epithelial phenotype and dissemination of cancer cells are early 
steps required for metastasis initiation in most solid tumors. We demonstrate that to acquire such 
metastatic capacity, FOXO3a and β-catenin act in concert, regulating functional sets of target 
genes involved in reorganizing the cytoskeleton, destabilizing cell-to-cell contacts, cell motility 
and migration, angiogenesis or evasion of the immune system (Supplementary Tables 1-4). 
These metastasis-related genes impose a cell-scattering phenotype that clearly differs from a 
canonical EMT, since levels of E-cadherin, Snail1, Snail2/Slug or Zeb1 are unchanged. 
Furthermore, we found that the expression of three of these target genes, IQGAP2, CLDN1 and 
CYR61, correlated positively with nuclear FOXO3a and β-catenin colocalization signal in primary 
carcinomas of colon-cancer patients. In particular, IQGAP2 colocalizes with E-cadherin in 
cytoplasmic aggregates in cancer cells that have lost their epithelial phenotype in vitro, in 
xenograft tumors and in human carcinomas. By knocking down its expression, we revealed 
IQGAP2 as a novel FOXO3a/β-catenin target gene required for destabilizing E-cadherin-
containing adherens junctions, for loss the epithelial phenotype and for enhanced cell motility. 
Furthermore, IQGAP2 expression correlated with cell scattering (tumor budding) in human colon 
carcinomas, indicating its role in invasion and metastasis. Since IQGAP2 knock-down partially 
altered the cell phenotype, we believe that what drives the final acquisition of cell motility and 
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metastatic potential is the coordinated activity of several FOXO3a/β-catenin target genes 
(Supplementary Fig. 11b-d). 
 Simultaneous accumulation of nuclear β-catenin and endogenous FOXO3a, upon AKT 
inhibition by API-2, promoted the synergistic induction of some of the aforementioned metastasis-
related target genes, suggesting their contribution to cancer-cell dissemination in nude mice. 
Indeed, API-2 accumulated nuclear FOXO3a and induced the expression of IQGAP2 in xenograft 
tumors from patient T49, which presented high endogenous levels of nuclear β-catenin. Such 
induction was accompanied by the loss of the epithelial phenotype similar to that observed in 
scattering HT29Fβ cells that metastasized in nude mice treated with API-2 and DOX. In fact, 
tumor budding actually correlates with the level of FOXO3a and β-catenin colocalization, which 
supports the notion that the effect observed in our experimental cell systems takes place in 
human carcinomas. 
  
Drug resistance is another crucial clinical feature that determines tumor relapse and patient 
survival. In particular, the mechanisms underlying resistance to novel PI3K or AKT inhibitors are 
largely unknown. One proposal is that activating mutations in RAS would trigger the down-stream 
RAF-MAPK pathway as an alternative way to survive treatment with pro-apoptotic PI3K or AKT 
inhibitors27,64. In addition, some mutations in PIK3CA (p110alpha) have been implicated in 
conferring resistance to specific inhibitors in vitro65. 
Part of the anti-tumoral action of PI3K and AKT inhibitors is based on nuclear FOXO 
accumulation and subsequent cell-cycle arrest and apoptosis20. Similarly, some anti-cancer drugs 
like 3-3´Diindolylmethane (B-DIM)66, or others widely used in the clinic such as doxorubicin or 
paclitaxel promote nuclear FOXO accumulation and apoptosis. In this scenario FOXO activation 
and cooperation with β-catenin may induce target genes that code for anti-oxidant scavenger 
enzymes such as SOD2 (MnSOD) to resist apoptosis20,53. 
We show that nuclear β-catenin activity acts as a new mechanism of resistance to FOXO3a-
induced apoptosis promoted by PI3K or AKT inhibitors. Thus, the induction of FOXO3a pro-
apoptotic target genes such as TNFSF10 (TRAIL) or BCL2L11 (BIM)67 is reduced by nuclear β-
 19
catenin, whereas FOXO3a and β-catenin cooperate synergistically to induce FASLG24. Such  
inhibitory effect of β-catenin could be a result of its binding to transcriptional co-repressors 
present at the promoters of these pro-apoptotic FOXO3a target genes12. We have identified the 
anti-apoptotic kinase HIPK3, which is responsible for FADD phosphorylation68 as a synergistically 
induced target gene of FOXO3a and β-catenin. This phosphorylation mediates FADD 
translocation to the nucleus, which confers resistance to death receptor-mediated apoptosis68-70. 
In this way, FOXO3a and β-catenin would block FASLG-induced apoptosis by inducing HIPK3 
and thus diverting the down-stream FADD-mediated signal. Therefore, β-catenin would favor the 
FASLG anti-apoptotic function thus enhancing its role in cell motility, invasion and metastasis and 
explaining its poor prognostic value in colon cancer71-74. In summary, our data indicate that β-
catenin activity modulates the dual role of FOXO3a as an inducer of cell death or cell survival. 
 
We describe a new mechanism by which FOXO3a and β-catenin commit cancer cells to 
either apoptotic or metastatic phenotypes. Such a mechanism occurs in colon carcinomas, which 
are heterogeneous tissues containing cell populations with diverse biological properties75,76. A β-
catenin paradox exists whereby individual cancer cells within genetically homogeneous 
populations (e.g. APC defective cells) accumulate different levels of nuclear β-catenin43,77. 
Numerous factors control the final level of nuclear β-catenin and, thus, the strength of the Wnt/β-
catenin signal. Classically, mutations in APC, but also activating mutations in K-RAS and different 
signals from tumor stroma like Hepatocyte Growth Factor or Lysophosphatidic Acid (LPA), entail 
nuclear β-catenin accumulation and cell diversity5,78-80.  Our data demonstrate that PI3K or AKT 
inhibitors promote nuclear FOXO3a accumulation and induce apoptosis only in cells with low 
nuclear β-catenin levels, and yet they reduce proliferation and promote metastasis of high nuclear 
β-catenin cells (Supplementary Fig. 21).  
We observed that only nuclear β-catenin-positive cells resisted FOXO3a-induced apoptosis 
while all the rest died either in vitro or in xenograft tumors. This selective apoptosis enriches 
resistant, high nuclear β-catenin cells upon long-term exposure to nuclear FOXO3a accumulation 
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in vitro, and also in subcutaneous tumors from patient-derived cells. Such cell selection by 
apoptosis would explain why we did not detect cancer cells with high nuclear FOXO3a and low β-
catenin levels in human colon carcinomas. Our data therefore do not support a switch of FOXO 
proteins from being inductors of apoptosis to being responsible for cell survival20, but rather a 
long-term selection of cancer cells with high nuclear β-catenin that are resistant to FOXO-induced 
apoptosis. 
In colon carcinomas, cell populations with high nuclear β-catenin content present a gene 
expression pattern similar to progenitor cells81 and behave as cancer stem cells with enhanced 
self-renewal capacity and pluripotency79. Our data indicate that this population could be more 
resistant to FOXO-induced apoptosis and responsible for later relapse. FOXO3a arrests the cell 
cycle, thus imposing quiescence on cancer cells with high nuclear β-catenin levels, which would 
normally proliferate intensively. Interestingly, FOXO-induced quiescence is crucial for self-
renewal and drug-resistance in normal and cancer stem cells82-84. Excess levels of β-catenin 
above the amounts needed to drive TCF/LEF target genes in APC-deficient cells may therefore 
regulate novel sets of FOXO target genes responsible for conferring stem-cell properties to colon 
cancer cells85. We show that some of these target genes are related to metastasis, supporting the 
notion of metastatic cancer stem cells, which have indeed been reported at the tumor invasive 
front of colon carcinomas79,86. 
Due to the limited availability of human colon cancer samples and the highly complex 
protocols needed to derive viable tumoral cells, few groups have yet explored the sensitivity of 
colon cancer patient-derived cells to anti-tumoral drugs in culture or, even less so, in vivo87,88. 
However, we applied our results to patient-derived colon-cancer initiating cells that complied with 
the fundamental properties of stem cells: self-renewal and pluripotency. These sphere cultures, 
which are enriched in cancer-initiating cells and which originated from tumors with high nuclear β-
catenin content, were resistant to PI3K and AKT inhibitors in vitro and in subcutaneous xenograft 
tumors.  
The information provided by these sphere cultures highlights the validity of studying target-
directed therapies in cells derived from colon tumors straight after surgical resection, since 
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patients could therefore benefit from a personalized, experiment-based decision on the optimal 
treatment. In the particular case of PI3K or AKT inhibitors, undesirable induction of FOXO3a and 
β-catenin target genes and promotion of metastasis could be predicted and avoided.  
We confirm that the tankyrase inhibitor XAV-939 reduces nuclear β-catenin levels51 and 
demonstrate that it sensitizes resistant cells specifically to FOXO3a-induced apoptosis promoted 
by PI3K or AKT inhibitors.  In contrast, it does not present any benefit when combined with 
conventional chemotherapeutic agents like 5-Fluorouracil (5-FU) or Oxaliplatin in cultures of colon 
cancer-initiating cells. This points to a valid strategy to overcome drug resistance and metastasis 
by combining PI3K or AKT and Wnt/β-catenin inhibitory drugs. Current Wnt signaling inhibitors 
have reduced activity in vivo, and a new generation of tankyrase inhibitors with satisfactory in vivo 
activity must be developed to translate our results to clinical practice. 
The benefit of some PI3K and AKT inhibitors is currently being tested in clinical trials in colon 
cancer patients with advanced metastatic disease29 and they may be tested as part of adjuvant 
therapy in the future. Our findings call for the measurement of nuclear β-catenin as a biomarker of 
response to treatments provoking FOXO3a nuclear accumulation, in order to predict apoptosis 
versus metastasis. This should be advisable for PI3K and AKT inhibitors, and may be extended to 
other drugs such as Cetuximab or Receptor Tyrosine Kinase inhibitors that act upstream of a 
common oncogenic pathway89-91. 
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FIGURE LEGENDS 
Figure 1. High nuclear FOXO3a and β-catenin levels correlate with metastatic stages and 
shorter survival in colon cancer patients. (a-c) Representative immunostained sections (left 
panels; Scale bar, 100 μm) and respective magnifications (right panels; Scale bar, 20 μm) of 
tumors with (a) low β-catenin and low FOXO3a, (b) high β-catenin and low FOXO3a, and (c) high 
β-catenin and high FOXO3a expression. FOXO3a (green), β-catenin (red), Hoechst 33342 (blue). 
Spearman´s coefficient of nuclear colocalization (r) is indicated. Merged magnified images lack 
blue channel and yellow color indicates FOXO3a and β-catenin colocalization. (d) Plot depicting 
nuclear FOXO3a and β-catenin immunofluorescent signal intensity in human colon carcinomas. 
Correlation was evaluated by non-parametric Spearman test. Number of cases (n), coefficient of 
correlation (r), and P values are indicated. Relative Units (r. u.) are calculated as explained in 
Methods section. (e) Column scatter plot showing the level of FOXO3a and β-catenin 
colocalization in tumors at different stages of colon cancer progression. Horizontal lines indicate 
arithmetic mean values with error bars showing the 95% confidence interval (CI). Number of 
cases (n) and P value for non-parametric ANOVA analysis with Kruskal-Wallis test are indicated. 
Asterisk marks significant difference between groups quantified by Dunn´s multiple comparison 
test. (f, h) Kaplan-Meier survival analysis of colon cancer patients separated into two groups by 
the median (f) or by the highest decile (h) for nuclear FOXO3a and β-catenin colocalization 
signal. Higher signal is in red (n = 58 in f, n = 11 in h) and lower signal in black (n = 55 in f, n = 
102 in h). P values are calculated by Log-rank (Mantel-Cox) test. (g) Plot representing nuclear 
immunofluorescent signal for FOXO3a and β-catenin colocalization. Dots of the highest decile 
values are marked in red.  
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Figure 2. FOXO3a and β-catenin control colon cancer cell proliferation and apoptosis. (a) 
Immunofluorescence analysis of FOXO3a (green) and β-catenin (red) expression in DLD1Fβ-C7 
cells treated as indicated. Scale bar, 50 μm. Lower panels show magnifications. Scale bar, 20 
μm. Nuclei were stained with Hoechst 33342 (blue). Merged magnification pictures lack the blue 
channel and yellow color indicates FOXO3a and β-catenin colocalization. (b) Normalized relative 
CDKN1A and LEF1 RNA expression levels in DLD1Fβ-C7 cells treated with DOX and/or 4OHT 
were measured by real-time RT-PCR. (c) Protein amounts of indicated proteins in DLD1Fβ-C7 
cells assessed by western blot. Flag-tag antibody detects exogenous Flag- β-CateninS33Y. 
FOXO3a antibody recognizes endogenous protein (lower band) and FOXO3a3A-ER fusion 
protein (upper band). Tubulin served as loading control. (d) Graphic showing proliferation of 
DLD1Fβ-C7 cells treated as indicated. (e) Chart depicting the percentage of apoptotic DLD1Fβ-
C7 cells in response to the indicated treatments measured by flow cytometry. The P value 
corresponds to an unpaired t test. (b,d,e) Error bars show +/- standard deviation (s.d.) of 
triplicates from three independent experiments. (f) Tumor growth in nude mice (n = 8, two 
tumors/animal) injected subcutaneously with DLD1Fβ cells and treated as indicated. Error bars 
show means +/- s.d. of volume of 16 tumors per treatment. (g) Graphic representing the 
percentage of apoptotic eGFP-β-cateninS33Y-positive (green bars) or negative subpopulations 
(black bars) of DLD1Fβ cells in tumors (n = 6) growing in nude mice treated as indicated. Bars 
show means and errors indicate +/- s.d. of the volume of six tumors per treatment. P values 
correspond to unpaired t tests.  
 
Figure 3. Nuclear FOXO3a and β-catenin drive cell scattering and metastasis. (a) 
Immunofluorescence analysis of DLD1Fβ-C7 cells treated as indicated detecting E-cadherin (red) 
and phalloidin-FITC-stained actin filaments (green). Scale bar, 100 μm. (b) Immunofluorescence 
analysis of E-cadherin in DLD1Fβ-C7 cells treated with 4OHT+DOX. Arrowheads indicate E-
cadherin cytosolic aggregates. Scale bar, 10 μm. (a,b,j) Nuclei were stained with Hoechst 33342 
(blue). (c) Scatter plot representing motility of DLD1Fβ-C7 cells treated as indicated showing the 
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distance covered by 50 individual cells in a time-lapse video recording one picture every 20 min 
during 120 h. Horizontal bars indicate means, errors show the 95% CI. (d) Graphic representing 
adhesion to the substrate of DLD1Fβ-C7 cells treated as indicated at five minutes post-seeding. 
Bars show means +/- s.d. of values of six replicates from two independent experiments. (c,d,h) P 
values for non-parametric ANOVA analyses with Kruskal-Wallis test are shown. Asterisks indicate 
significant differences between groups upon Dunn´s multiple comparison tests. (e) Incidence of 
metastasis in mice injected in the cecum with HT29Fβ cells and treated as indicated. L.N. = 
lymph node, Carc. = carcinomatosis, including any tumor mass growing in the abdominal cavity 
eventually affecting adjacent organs. Ratios indicate the numbers of animals with affected tissue 
per total number in each group of treatment. P values listed in brackets were calculated vs. 
vehicle by Fisher’s exact test. Only metastases detected by luminometry and confirmed by 
histological exploration were taken into account. (f) Bioluminescence imaging (IVIS®) of organs 
obtained upon necropsy of nude mice bearing orthotopic tumors from cecum-injected HT29Fβ 
cells. Left: Images overlaid with gradual bioluminescent signal (blue < red) originated from 
luciferase-expressing metastatic cells. Right: Hematoxylin & eosin staining of the corresponding 
histological sections. Carc. = carcinomatosis; Ing. = inguinal. Scale bar, 100 μm. (g) Hematoxylin 
& eosin stained histological section of the invasive front of a primary tumor xenograft from 
HT29Fβ cells growing in the cecum wall of nude mice treated with 4OHT+ DOX (e). (h) Column 
scatter plot presenting tumor budding in primary tumors described in (e). n indicates the number 
of tumors analyzed. Horizontal bars show the mean and the 95% CI. P values for non-parametric 
ANOVA analyses with Kruskal-Wallis test are shown. Asterisks indicate significant differences 
between groups upon Dunn´s multiple comparison tests. (i) Hematoxylin & eosin stained 
histological section of the invasive front of a primary human colon carcinoma. Dashed square 
marks the area shown in panel j. (g,i) Dashed line delineates tumor edge. T = tumor bulk; M = 
muscle. Black arrowheads indicate budding tumor cells. Scale bar, 100 μm. (j) 
Immunofluorescent staining of the invasive front of a human primary colon carcinoma for 
FOXO3a (green) and β-catenin (red). Nuclei were stained with Hoechst 33342 (blue). White 
arrowheads indicate budding tumor cells. Right panels show magnifications. The merged 
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magnified image lacks the blue channel and yellow color indicates FOXO3a and β-catenin 
colocalization. Scale bar, 100 μm and 20 μm in magnification pictures. (j) Dot plot representing 
the correlation of nuclear FOXO3a and β-catenin immunofluorescence signal with the incidence 
of tumor budding in 65 human primary colon carcinomas. Correlation was evaluated by non-
parametric Spearman test. Number of cases (n), coefficient of correlation (r), and P values are 
indicated. Tumor budding and relative units (r. u.) of nuclear FOXO3a & β-catenin content are 
calculated as explained in Methods section. 
 
Figure 4. FOXO3a and β-catenin regulate a defined gene expression program. (a) Gene 
clustering diagram calculated on Robust Multi-Array (RMA)-normalized expression values upon 
genome wide microarray analysis. Cells were treated as labeled for 24 hours. Triplicates of each 
treatment are indicated as colored rectangles at the bottom. Significance level: two-tailed ANOVA 
P value ≤ 0.05. Scaling, low (green) to high (red). (b) Venn-Diagram representing the number of 
genes regulated by the indicated treatments (24h) upon high-stringency analysis (cut-off 
Bonferroni: P value ≤ 0.05) and a two-fold change versus control (≥ 2) in at least one of the 
conditions (Supplementary Table 2). (c) Plot representing changes in the relative expression 
levels of regulated genes comparing 4OHT+DOX and 4OHT treatments. Red, higher than two-
fold induction; green, lower than two-fold repression. (d) Metastasis signature. Heat map of RMA-
normalized expression values for genes described to be involved in metastasis. Triplicates for 
each treatment are shown. Green tones, low expression; red tones, high expression. (e) Gene 
expression values of metastasis signature genes are shown as fold change for the indicated 
treatments. Official gene symbols and HGNC Gene Names are listed. n.s., not significant. (f) 
Mean relative mRNA expression levels of IQGAP2, CYR61 and CLDN1 transcripts measured by 
real-time RT-PCR in DLD1Fβ-C7 cells upon indicated treatments. Error bars, triplicate values +/- 
s.d. obtained in three independent experiments. (g) Western blot analysis of the indicated 
proteins in DLD1Fβ-C7 cells. Numbers below the blot represent relative amount of each protein 
versus vehicle-treated cells. All values are corrected by their respective Tubulin signal that served 
as loading control. (h) Dot plot representing immunofluorescent signal intensity for each indicated 
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protein correlated to nuclear FOXO3a & β-catenin colocalization signal intensity in 59 human 
colon carcinomas analyzed. Correlation was evaluated by non-parametric Spearman test. 
Number of patients (n), coefficient of correlation (r) and P values are indicated. Relative units (r. 
u.) were calculated as explained in Methods section. 
 
Figure 5. AKT inhibition by API-2 promotes metastasis of cells with high nuclear β-catenin. 
(a) Relative mRNA levels of the indicated genes measured by real-time RT-PCR in DLD1Fβ-C7 
cells treated with API-2 and/or DOX as shown. Error bars are +/- s.d. of triplicates from three 
independent experiments. (b) Immunofluorescence analysis of FOXO3a (red) and β-catenin 
(green) expression in primary tumors growing in the cecum of nude mice. Scale bar, 100 μm. 
Right panels: Magnification of cells within the primary tumors. Scale bar, 25 μm. Nuclei were 
stained with Hoechst 33342 (blue). (c) Kaplan-Meier analysis of bioluminiscence (BLI) 
representing the percentage of nude mice injected in the cecum with HT29Fβ cells and treated as 
indicated that retain the signal along time. Number of animals used is indicated in panel d. (d) 
Incidence of metastasis in mice injected in the cecum with HT29Fβ cells and treated as indicated. 
L.N. = lymph node, Carc. = carcinomatosis, including any tumor mass growing in the abdominal 
cavity eventually affecting adjacent organs. Ratios indicate the numbers of animals with affected 
tissue per total number in each group of treatment. P values listed in brackets were calculated vs. 
vehicle by Fisher’s exact test. Only metastases detected by luminometry and confirmed by 
histological exploration were taken into account. (e) Ex vivo image of infiltrated liver overlaid with 
gradual false-colored bioluminescent signal (blue, low; red, high). (f) Hematoxylin & eosin staining 
of liver metastasis from a cecum-injected mouse treated with API-2+DOX as described in (d). 
Scale bar, 200 μm. Insert shows a magnification with dashed line marking tumor-liver edge; T = 
tumor, L = liver tissue. Scale bar, 100 μm. 
 
Figure 6. High nuclear β-catenin level confers colon cancer patient-derived cells resistance 
to PI3K-AKT inhibitors. (a) Hematoxylin & eosin staining of patients’ primary carcinomas (left) 
and subcutaneous tumors (right, xenograft) generated in NOD-SCID mice from the corresponding 
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patient-derived cells. Scale bar, 100 μm. (b) Immunofluorescent staining for β-catenin (red) in 
patients‘ primary carcinomas (left) and corresponding subcutaneous xenograft tumors in mice 
(right). Right inserts correspond to magnifications that show the amount of nuclear β-catenin. 
Nuclei were stained with Hoechst 33342 (blue). Scale bar, 100 μm and right inserts 50 μm. (c) 
Percentages of apoptotic cells in patient-derived sphere cultures treated as indicated. Apoptosis 
was measured by flow cytometry. Bars represent the mean of three independent experiments. 
Error bars are +/- s.d. Cells were treated with the mentioned compounds as described in Methods 
section. (d) Graph representing the amount of nuclear β-catenin measured by 
immunofluorescence in the primary colon carcinomas of each indicated patient. Relative units (r. 
u.) were calculated as explained in Methods section. (e) Cancer cells derived from the three 
indicated patients’ tumors were injected subcutaneously in NOD-SCID mice and treated with API-
2 or vehicle (n = 5, two flanks/animal). Arrows mark the initiation of treatment. The represented 
fold change is calculated comparing tumor volume at each given time point versus the volume at 
first day of treatment. Relative units (r. u.) were calculated as explained in Methods section. Error 
bars are +/- s.d. of ten tumors per treatment. P values correspond to non-parametric Mann-
Whitney test. Asterisks indicate significant differences between volumes of tumors growing in 
mice treated with vehicle versus API-2. (f) Upper panels: Immunofluorescent staining for FOXO3a 
(green) and β-catenin (red) in histological sections of subcutaneous xenografted tumors from 
patient T49 treated as indicated. Right panels correspond to magnifications that show amounts of 
nuclear FOXO3a and β-catenin. Scale bar, 100 μm and right panel 50 μm. Lower panels show 
immunofluorescent staining for IQGAP2 (red) in the same xenograft tumors. Insert shows a 
magnification of cells with IQGAP2 accumulated in cytoplasmic aggregates. Scale bar, 100 μm 
and insert 50 μm. Nuclei were stained with Hoechst 33342 (blue). (g) Column scatter plots 
representing the levels of expression for each indicated protein in xenografted tumors from 
patient T49 treated as labeled. Five pictures were quantified per each of the four tumors treated. 
P values correspond to non-parametric Mann-Whitney test comparing the values of protein 
expression in each quantified picture. Relative units (r. u.) were calculated as explained in 
Methods section. 
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METHODS 
Cell Culture 
Human colon-cancer cell lines were cultured in DMEM, 10% FBS and penicillin/streptomycin 
(Invitrogen). DLD1 cells were transfected with pcDNA-FoxO3a(3A)ERTM 36 and neomycin-
selected to obtain a pool of DLD1F cells. HT29 and HCT116 colon-cancer cell lines were 
transduced with pLHCX-HA-FoxO3a(3A):ERTM retrovirus to generate HT29F and HCT116F. 
HT29F cells were additionally transfected with pGL4.51[luc2/CMV/Neo] (Promega). β-cateninS33Y 
was introduced in DLD1F and HT29F by infection with pSIN-TRE-flag-β-CateninS33Y-IRES-GFP 
inducible lentivirus to generate DLD1Fβ and HT29Fβ cell lines. Proliferation rates of cultured cells 
were assessed using the Cell Proliferation Kit II (XTT; Roche Molecular Biochemicals). Cell 
migration was quantified by filming cells for 120 h using a time-lapse microscope (3 frames/h, 
Olympus TiRF™ Microscope). The distance covered by 50 individual cells for each condition was 
measured using the cell-tracking plugin of the ImageJ software (Rasband, W.S., NIH, USA). 
Adhesion to substrate was quantified by using a spectrometer to measure quantity of crystal 
violet staining retained by cells attached to the plastic culture dish five minutes post-seeding. 
Senescence-associated (SA) β-galactosidase activity was determined using the Senescence 
Cells Histochemical Staining Kit (Sigma). 
 
Patient-derived cells 
Primary human colon-cancer cells were obtained from adenocarcinomas corresponding to six 
patients immediately after surgery. In all cases written informed consent was signed. The project 
including human samples was evaluated and accepted by the Research Ethics Committee from 
Vall d'Hebron University Hospital, Barcelona, Spain (Approval ID: PR(IR)79/2009). Staging and 
grade were assigned by histopathological evaluation at the Pathology Service of Vall d´Hebron 
Hospital. Cells were derived from patients’ samples and sphere cultures in suspension were 
obtained as described previously87,92.  
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Animals, xenotransplantation and bioluminescence 
Animals were handled according to the European Union’s animal care directive (86/609/EEC). 
Experiments were approved by the Ethical Committee of Animal Experimentation of Vall d’Hebron 
Institute of Research (ID: 40/08 CEEA and ID: 47/08/10 CEEA). NOD-SCID (NOD.CB17-
Prkdcscid/NcrCrl) and Nude mice (Crl:NU-Foxn1nu) were purchased from Charles River 
Laboratories. Cells mixed with Matrigel (1:1 v/v-ratio; BD Biosciences) were injected 
subcutaneously into the flanks of NOD-SCID or Nude mice. For orthotopic transplantation, colon-
cancer cells were injected in the cecum wall of mice as previously described93. All mice injected 
were female littermates between 8 and 12 weeks of age. DOX (2 mg/ml; Sigma-Aldrich) was 
administered ad libidum in drinking water containing 5 % sucrose (Sigma-Aldrich). 4OH-
Tamoxifen (100 μg/dose; 1 μg/μl in sesame oil; Sigma-Aldrich) and API2 (1 mg/kg in PBS-2% 
DMSO; Tocris Bioscience) were injected intraperitoneally (i.p.) every second day. Tumor growth 
was calculated as fold increase of the average sphere volume (V = 4/3 x πr3, where r = (L + W)/2) 
versus tumor volume at the beginning of treatment. Treatments were initiated once subcutaneous 
tumors reached 0.5 cm3. In vivo and ex vivo bioluminescence imaging was performed with the 
IVIS® Spectrum Imaging System and Living Image® 4.0 software (Caliper Life Sciences). Animals 
were given 150 mg/kg i.p. of D-luciferin (Promega), and 9 minutes later either in vivo images were 
acquired under anaesthesia or animals were sacrificed and necropsy was performed for ex vivo 
imaging.  
 
Western blot, histology and immunofluorescence  
Western blot was carried out and quantified as described94. Nuclear/cytoplasmic fractionation was  
as described elsewhere95. Tumor budding was quantified as previously described41,42. 
Immunofluorescence was performed on fixed paraffin-embedded sections or on fixed cells 
cultured on glass coverslips as described94. Pictures were taken using an Olympus FluoView-
FV1000 Confocal Microscope. All antibodies used are listed in Supplementary Table 7. Nuclear 
staining was done with Hoechst 33342 at 5 μg/ml (Sigma-Aldrich). 
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To analyze FOXO3a, β-catenin, IQGAP2, CLDN1 and CYR61 expression in patients’ colon 
tumors, serial histological sections of low-density tissue microarrays were immunostained with 
specific antibodies and counter-stained with Hoechst 33342. Signals were acquired using the 
HistoRX microscope and Automated Quantitative Analysis (AQUA®) system. Fluorescence image 
data were analyzed with the MBF "ImageJ for Microscopy"-program collection of plugins 
(www.macbiophotonics.ca) using criteria described earlier94. Briefly, we defined Regions of 
Interest (ROI) in images of immunostained tissue arrays encompassing only tumoral tissue. First, 
using ImageJ software, we obtained the integrated density value and each channel-molecule 
(e.g. FOXO3a, green channel; β-catenin, red channel) and Hoechst 33342 (blue channel) for 
each ROI. Next, we measured the integrated density for Hoechst signal present in each ROI and 
normalized by a standard nucleus signal, defined as the average integrated density of ten nuclei 
taken at random. The resulting values correspond to the number of nuclei and, therefore, to the 
number of cells present in each ROI. Finally, we divided the values of the integrated density for 
each protein of interest (green or red channels) by the calculated number of cancer cells in the 
corresponding ROI. These values indicate the level of expression for each protein per cancer cell 
analyzed noted as relative units (r. u.) in the corresponding figures. To obtain FOXO3a and β-
catenin colocalization signal we first calculated, using ImageJ software, the integrated density of 
the coincident signal between green (FOXO3a) and red (β-catenin) channels in the corresponding 
ROI. Values were then normalized to the number of cancer cells, calculated as explained above 
(Hoechst, blue channel).  
 
Flow cytometry 
Analyses were done using FACScalibur and LSRII cytometers (BD Bioscience). Proportions of 
apoptotic cells were determined on trypsin-dissociated colon-cancer cell lines or minced tumor 
tissues using the following kits: Annexin V-eGFP (GenScript Corporation), Annexin V-PE (BD 
Pharmingen) or Annexin-V-APC (Bender MedSystems). Anti-human TRA-85-APC antibody (R&D 
Systems) were used to discriminate human from mouse cells when samples were derived from 
xenograft tumors growing in mice. Dead cells were detected by using propidium iodide or DAPI 
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staining.  The cell-cycle profile was acquired with ethanol-fixed cells stained with propidium 
iodide. For data analysis we used FCS-express3 flow cytometer software (DeNovo Software).  
 
Quantitative RT-PCR and Transcriptomics 
RNA was isolated by the TRIZOL method (Invitrogen) and cDNA was synthesized using 
Superscript-III reverse transcriptase (Invitrogen). A 7900HT qPCR System was used with Power 
SYBR-green (Applied Biosystems) and specific pairs of primers (Supplementary Table 8). 
Relative gene expression was determined by the comparative CT method96. We applied geNorm 
algorithms97 to select succinate dehydrogenase flavoprotein subunit (SDHA) and peptidylprolyl 
isomerase A (cyclophilin A, PPIA) as reference transcripts to use geometric means for 
normalization and to calculate normalized standard deviation from triplicates of three independent 
experiments.  
The transcriptome of DLD1Fβ-C7 cells was determined on a genome wide Human Gene 1.1 ST 
Array (Affimetrix). RNA of experimental triplicates treated with vehicle or with 4OHT (50 nM) and 
DOX (2.5 μg/ml; 12 h pretreatment) separately or in combination was analyzed at 12 h and 24 h 
after combined treatment. Microarray data was acquired using the Affimetrix 
GeneChip/GeneTitan platforms. We performed Gene Set Enrichment Analysis (GSEA, 
www.broadinstitute.org) comparing RMA-normalized probe sets to molecular signature gene sets 
(Gene Ontology Consortium). A subsequent cut-off at two-tailed ANOVA P value ≤ 0.05 yielded 
8229 regulated probes at 12 h and 8479 probes at 24 h, which were used for clustering. To obtain 
high-stringency gene lists encompassing fold-change values of 515 genes (12 h) and 874 genes 
(24 h) (Supplementary Table 1 and 2) data were collapsed-down to annotated genes (Unigene; 
NCBI) and further cut off at a significance level of Bonferroni adjusted P value ≤ 0.05 (≈ FDR P 
value ≤ 0.00005) and minimum two-fold change vs. control (vehicle) in at least one condition. 
Raw and normalized MIAME-compliant microarray data were deposited in ARRAYEXPRESS 
(www.ebi.ac.uk/arrayexpress/) under Accession Number E-MEXP-3262. 
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Mutational status of patient-derived cells and cancer cell lines 
Samples were genotyped for 740 mutations associated with tumors, which affected 57 genes. 
OncoCarta (Sequenom), CLIA (MD Anderson Cancer Center, Houston, TX) and VHIO-Card 
panels of somatic mutations (Supplementary Table 6) were analyzed with a MassARRAY 
spectrometer (Sequenom) as published98. Mutation data were obtained from the Sanger 
Institute’s COSMIC database (www.sanger.ac.uk/cosmic). Microsatellite instability was analyzed 
using the MSI-Analysis System (Promega). Loss of nuclear expression of mismatch-repair 
proteins (MLH1, MSH2, MSH6, PMS2) was assessed by immunohistochemistry.  
 
Plasmids 
The Tet-inducible lentiviral plasmid pSIN-TRE-flag-β-CateninS33Y-IRES-GFP was constructed 
using an IRES-GFP cassette-containing derivate99 of pRRL-cPPT-hPGK-TMPrtTA-WPRE 
plasmid100 introducing the human flag-β-CateninS33Y cds (MluI). Retroviral plasmid pLHCX-HA-
FoxO3a(A3):ERTM was cloned inserting FOXO3a(A3):ERTM construct36 HindIII/ClaI in pLHCX 
(Clontech). The lentiviral reporter 7TGP was previously described101. Lentiviral shRNAmir-
constructs in the pGIPZ vector to knock-down IQGAP2 expression were purchased from Open 
Biosystems (Supplementary table 8b). ZEB1 and SLUG expression vectors were a kind gift from 
A. Muñoz laboratory (Madrid, Spain). 
 
Reagents and treatments 
Unless specified otherwise, cells were treated under the following conditions: DOX, 2.5 μg/ml for 
36 h (DOX, Sigma-Aldrich), 12 h previous to 4-Hydroxy-Tamoxifen, 50 nM for 24 h (4OHT, 
Sigma-Aldrich). XAV-939, 3.3 μM or LDW-643 (Novartis) for 120 h, 48 h previous to LY-294002, 
20 μM (Merck), API-2, 20 μM (Tocris Bioscience), NVP-BKM120, 0.8 μM (Selleck Chemicals), 5-
Fluorouracil, 50 μg/ml (5-FU; Sigma-Aldrich) or Oxaliplatin, 100 μM (Sigma-Aldrich) for 72 h. 
LDW-643 is an analogue of XAV-939 with no biological activity that was used to treat control cells 
in all experiments in which XAV-939 was tested. Mitomycin C (10 μg/ml for 3 h) was used 24 h 
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prior to additional treatments. Human primary fibroblasts were treated with Doxorubicin at 0.1 μM 
for 24 h to induce senescent phenotype within the ten following days. 
 
Viral infection 
Lentiviral particles were produced by transfecting 293T cells with lentiviral constructs and 
packaging vectors (psPAX2 and pMD2.G, Addgene). Analogously, we produced retrovirus using 
retroviral plasmids and pCL-Ampho packaging construct (Imgenex Corp.). 
 
Statistics 
To calculate the correlation coefficient (r) between fluorescent signal values of different proteins 
or with tumor budding in tissue sections of human carcinomas (Fig. 1h, Fig. 3k, Fig. 4h and 
Supplementary Fig. 1a,b, 12f, 15a,b), we used a two-tailed non-parametric Spearman test which 
makes no assumption about the distribution of the values. Using MBF "ImageJ for Microscopy"-
program we also obtained Spearman´s correlation coefficient (r) corresponding to colocalization 
between nuclear FOXO3a and β-catenin (Fig.1a), E-cadherin and actin (Supplementary Fig. 6f, 
12c,d), E-cadherin and IQGAP2 (Supplementary Fig. 13b,d) or IQGAP2 and Hoechst 33342 
(Supplementary Fig. 13b,d). We used a non-parametric Kruskal-Wallis test to compare the values 
obtained for nuclear β-catenin, FOXO3a or their colocalization in human carcinomas at different 
tumor stages (Fig. 1e and Supplementary Figure 1c,d), to compare different treatments in cell 
motility and adhesion assays (Fig. 3c,d), to compare tumor budding in primary tumors growing in 
the cecum wall of nude mice (Fig. 3h), or nuclear β-catenin content in different cell lines 
(Supplementary Fig. 18a). We used this test because it allowed us to compare three or more 
groups of values which were unpaired and did not follow any particular distribution. We also used 
a Dunn’s multiple comparison post-test to identify differences in the sum of ranks between each 
pair of group of values. To analyze survival of colon cancer patients (Fig. 1f,h and Supplementary 
Fig. 1e,f) we used the Kaplan-Meier method and compared the curves using a Log-rank (Mantel-
Cox) test. This is the best test assuming that the hazard function (deaths per time) is the same at 
all times. We used the non-parametric Mann Whitney test to compare the unmatched groups of 
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values corresponding to xenograft tumour volumes or luminescence signal (Fig. 6e and 
Supplementary Fig. 8b), tissue protein expression (Fig. 6g, Supplementary Fig. 2a, 5e, 10d, 
17a,c,e, 20b) and cell motility of IQGAP2 knock down cells (Supplementary Fig. 12e). To 
evaluate the effect of treatments on the proportion of apoptotic cells (Fig. 2e,g), we used an 
unpaired t test to compare the means of the two groups of values. We used a Fisher’s exact test 
to analyze the differences in metastasis frequency between groups of treated mice (Fig. 3e, Fig. 
5d and Supplementary Fig. 8d). All groups of mice were compared with vehicle-treated animals. 
 
REFERENCES 
 
1. Jemal, A., et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 
69-90 (2011). 
2. Janne, P.A. & Mayer, R.J. Chemoprevention of colorectal cancer. The New 
England journal of medicine 342, 1960-1968 (2000). 
3. Levine, J.S. & Ahnen, D.J. Clinical practice. Adenomatous polyps of the colon. 
The New England journal of medicine 355, 2551-2557 (2006). 
4. Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. 
Science 307, 1904-1909 (2005). 
5. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 127, 
469-480 (2006). 
6. MacDonald, B.T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Dev Cell 17, 9-26 (2009). 
7. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843-
850 (2005). 
8. Gregorieff, A. & Clevers, H. Wnt signaling in the intestinal epithelium: from 
endoderm to cancer. Genes Dev 19, 877-890 (2005). 
9. Palmer, H.G. Vitamin D3 promotes the differentiation of colon carcinoma cells by 
the induction of E-cadherin and the inhibition of beta-catenin signaling. The 
Journal of Cell Biology 154, 369-388 (2001). 
10. Palmer, H.G., Anjos-Afonso, F., Carmeliet, G., Takeda, H. & Watt, F.M. The 
vitamin D receptor is a Wnt effector that controls hair follicle differentiation and 
specifies tumor type in adult epidermis. PLoS One 3, e1483 (2008). 
11. Jones, P.H., Simons, B.D. & Watt, F.M. Sic transit gloria: farewell to the 
epidermal transit amplifying cell? Cell stem cell 1, 371-381 (2007). 
12. Olson, L.E., et al. Homeodomain-mediated beta-catenin-dependent switching 
events dictate cell-lineage determination. Cell 125, 593-605 (2006). 
13. Mulholland, D.J., Dedhar, S., Coetzee, G.A. & Nelson, C.C. Interaction of nuclear 
receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? 
Endocr Rev 26, 898-915 (2005). 
14. Essers, M.A., et al. Functional interaction between beta-catenin and FOXO in 
oxidative stress signaling. Science 308, 1181-1184 (2005). 
 37
15. Calnan, D.R. & Brunet, A. The FoxO code. Oncogene 27, 2276-2288 (2008). 
16. Burgering, B.M. A brief introduction to FOXOlogy. Oncogene 27, 2258-2262 
(2008). 
17. van der Horst, A. & Burgering, B.M. Stressing the role of FoxO proteins in 
lifespan and disease. Nat Rev Mol Cell Biol 8, 440-450 (2007). 
18. Huang, H. & Tindall, D.J. Dynamic FoxO transcription factors. Journal of cell 
science 120, 2479-2487 (2007). 
19. van der Vos, K.E. & Coffer, P.J. The extending network of FOXO transcriptional 
target genes. Antioxidants & redox signaling 14, 579-592 (2011). 
20. Gomes, A.R., Brosens, J.J. & Lam, E.W. Resist or die: FOXO transcription 
factors determine the cellular response to chemotherapy. Cell cycle (Georgetown, 
Tex 7, 3133-3136 (2008). 
21. Myatt, S.S., Brosens, J.J. & Lam, E.W. Sense and sensitivity: FOXO and ROS in 
cancer development and treatment. Antioxidants & redox signaling 14, 675-687 
(2011). 
22. Myatt, S.S. & Lam, E.W. The emerging roles of forkhead box (Fox) proteins in 
cancer. Nat Rev Cancer 7, 847-859 (2007). 
23. Greer, E.L. & Brunet, A. FOXO transcription factors at the interface between 
longevity and tumor suppression. Oncogene 24, 7410-7425 (2005). 
24. Brunet, A., et al. Akt promotes cell survival by phosphorylating and inhibiting a 
Forkhead transcription factor. Cell 96, 857-868 (1999). 
25. Dehner, M., Hadjihannas, M., Weiske, J., Huber, O. & Behrens, J. Wnt signaling 
inhibits Forkhead box O3a-induced transcription and apoptosis through up-
regulation of serum- and glucocorticoid-inducible kinase 1. J Biol Chem 283, 
19201-19210 (2008). 
26. Walther, A., et al. Genetic prognostic and predictive markers in colorectal cancer. 
Nat Rev Cancer 9, 489-499 (2009). 
27. Liu, P., Cheng, H., Roberts, T.M. & Zhao, J.J. Targeting the phosphoinositide 3-
kinase pathway in cancer. Nat Rev Drug Discov 8, 627-644 (2009). 
28. Ihle, N.T. & Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors 
race through the clinic and toward cancer therapy. Molecular cancer therapeutics 
8, 1-9 (2009). 
29. Dienstmann, R., Rodon, J., Markman, B. & Tabernero, J. Recent developments in 
anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer 
Drug Discov 6, 210-236 (2011). 
30. Markman, B., Atzori, F., Perez-Garcia, J., Tabernero, J. & Baselga, J. Status of 
PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21, 
683-691 (2010). 
31. Morris, R.J., et al. Capturing and profiling adult hair follicle stem cells. Nat 
Biotechnol 22, 411-417 (2004). 
32. Zheng, Y., et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 
induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity 
with dexamethasone. J Mol Med (Berl) (2011). 
33. Garrett, C.R., et al. Phase I pharmacokinetic and pharmacodynamic study of 
triciribine phosphate monohydrate, a small-molecule inhibitor of AKT 
 38
phosphorylation, in adult subjects with solid tumors containing activated AKT. 
Invest New Drugs (2010). 
34. Hoffman, K., et al. Phase I-II study: triciribine (tricyclic nucleoside phosphate) 
for metastatic breast cancer. Cancer Chemother Pharmacol 37, 254-258 (1996). 
35. Bendell, J.C., et al. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-
Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol 30, 
282-290 (2012). 
36. Dijkers, P.F., Medema, R.H., Lammers, J.W., Koenderman, L. & Coffer, P.J. 
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the 
forkhead transcription factor FKHR-L1. Curr Biol 10, 1201-1204 (2000). 
37. Seoane, J., Le, H.V., Shen, L., Anderson, S.A. & Massague, J. Integration of 
Smad and forkhead pathways in the control of neuroepithelial and glioblastoma 
cell proliferation. Cell 117, 211-223 (2004). 
38. Hoogeboom, D., et al. Interaction of FOXO with beta-catenin inhibits beta-
catenin/T cell factor activity. J Biol Chem 283, 9224-9230 (2008). 
39. Kops, G.J., et al. Control of cell cycle exit and entry by protein kinase B-
regulated forkhead transcription factors. Mol Cell Biol 22, 2025-2036 (2002). 
40. Nobes, C.D. & Hall, A. Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, 
and filopodia. Cell 81, 53-62 (1995). 
41. Ueno, H., Murphy, J., Jass, J.R., Mochizuki, H. & Talbot, I.C. Tumour 'budding' 
as an index to estimate the potential of aggressiveness in rectal cancer. 
Histopathology 40, 127-132 (2002). 
42. Prall, F., Nizze, H. & Barten, M. Tumour budding as prognostic factor in stage 
I/II colorectal carcinoma. Histopathology 47, 17-24 (2005). 
43. Brabletz, T., et al. Variable beta-catenin expression in colorectal cancers indicates 
tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 
98, 10356-10361 (2001). 
44. Delpuech, O., et al. Induction of Mxi1-SR alpha by FOXO3a contributes to 
repression of Myc-dependent gene expression. Molecular and cellular biology 27, 
4917-4930 (2007). 
45. Wells, C.D., et al. A Rich1/Amot complex regulates the Cdc42 GTPase and 
apical-polarity proteins in epithelial cells. Cell 125, 535-548 (2006). 
46. Kaibuchi, K., Kuroda, S., Fukata, M. & Nakagawa, M. Regulation of cadherin-
mediated cell-cell adhesion by the Rho family GTPases. Curr Opin Cell Biol 11, 
591-596 (1999). 
47. Yamashiro, S., Abe, H. & Mabuchi, I. IQGAP2 is required for the cadherin-
mediated cell-to-cell adhesion in Xenopus laevis embryos. Dev Biol 308, 485-493 
(2007). 
48. Natale, D.R. & Watson, A.J. Rac-1 and IQGAP are potential regulators of E-
cadherin-catenin interactions during murine preimplantation development. Gene 
Expr Patterns 2, 17-22 (2002). 
49. Tsai, M.S., Hornby, A.E., Lakins, J. & Lupu, R. Expression and function of 
CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. 
Cancer Res 60, 5603-5607 (2000). 
 39
50. Dhawan, P., et al. Claudin-1 regulates cellular transformation and metastatic 
behavior in colon cancer. J Clin Invest 115, 1765-1776 (2005). 
51. Huang, S.M., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt 
signalling. Nature 461, 614-620 (2009). 
52. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. 
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. 
Nature 378, 785-789 (1995). 
53. Kops, G.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells 
from oxidative stress. Nature 419, 316-321 (2002). 
54. Chu, P., et al. Characterization of a subpopulation of colon cancer cells with stem 
cell-like properties. Int J Cancer 124, 1312-1321 (2009). 
55. Wu, B., Crampton, S.P. & Hughes, C.C. Wnt signaling induces matrix 
metalloproteinase expression and regulates T cell transmigration. Immunity 26, 
227-239 (2007). 
56. Brabletz, T., Jung, A., Dag, S., Hlubek, F. & Kirchner, T. beta-catenin regulates 
the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J 
Pathol 155, 1033-1038 (1999). 
57. Mann, B., et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-
factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 96, 
1603-1608 (1999). 
58. Howe, L.R., Watanabe, O., Leonard, J. & Brown, A.M. Twist is up-regulated in 
response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer 
research 63, 1906-1913 (2003). 
59. Samuels, Y., et al. Mutant PIK3CA promotes cell growth and invasion of human 
cancer cells. Cancer cell 7, 561-573 (2005). 
60. Yoeli-Lerner, M., et al. Akt blocks breast cancer cell motility and invasion 
through the transcription factor NFAT. Mol Cell 20, 539-550 (2005). 
61. Chen, J., et al. Constitutively nuclear FOXO3a localization predicts poor survival 
and promotes Akt phosphorylation in breast cancer. PloS one 5, e12293 (2010). 
62. Storz, P., Doppler, H., Copland, J.A., Simpson, K.J. & Toker, A. FOXO3a 
promotes tumor cell invasion through the induction of matrix metalloproteinases. 
Molecular and cellular biology 29, 4906-4917 (2009). 
63. Paik, J.H., et al. FoxOs are lineage-restricted redundant tumor suppressors and 
regulate endothelial cell homeostasis. Cell 128, 309-323 (2007). 
64. Jun, T., Gjoerup, O. & Roberts, T.M. Tangled webs: evidence of cross-talk 
between c-Raf-1 and Akt. Sci STKE 1999, PE1 (1999). 
65. Zunder, E.R., Knight, Z.A., Houseman, B.T., Apsel, B. & Shokat, K.M. 
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K 
isoform p110 alpha. Cancer cell 14, 180-192 (2008). 
66. Li, Y., et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-
diindolylmethane contributes to inhibition of cell proliferation and induction of 
apoptosis in prostate cancer cells. J Biol Chem 282, 21542-21550 (2007). 
67. Obexer, P., Geiger, K., Ambros, P.F., Meister, B. & Ausserlechner, M.J. 
FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the 
mitochondria in neuroblastoma cells. Cell death and differentiation 14, 534-547 
(2007). 
 40
68. Rochat-Steiner, V., et al. FIST/HIPK3: a Fas/FADD-interacting serine/threonine 
kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-
terminal kinase activation. J Exp Med 192, 1165-1174 (2000). 
69. Curtin, J.F. & Cotter, T.G. JNK regulates HIPK3 expression and promotes 
resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol 
Chem 279, 17090-17100 (2004). 
70. Tourneur, L. & Chiocchia, G. FADD: a regulator of life and death. Trends in 
immunology 31, 260-269 (2010). 
71. Peter, M.E., et al. The CD95 receptor: apoptosis revisited. Cell 129, 447-450 
(2007). 
72. Barnhart, B.C., et al. CD95 ligand induces motility and invasiveness of apoptosis-
resistant tumor cells. Embo J 23, 3175-3185 (2004). 
73. Liu, K., McDuffie, E. & Abrams, S.I. Exposure of human primary colon 
carcinoma cells to anti-Fas interactions influences the emergence of pre-existing 
Fas-resistant metastatic subpopulations. Journal of immunology 171, 4164-4174 
(2003). 
74. Yokomizo, H., et al. Fas ligand expression is a risk factor for liver metastasis in 
colorectal cancer with venous invasion. Anticancer research 23, 5221-5224 
(2003). 
75. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat Med 17, 
313-319 (2011). 
76. Shackleton, M., Quintana, E., Fearon, E.R. & Morrison, S.J. Heterogeneity in 
cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009). 
77. Fodde, R. & Brabletz, T. Wnt/beta-catenin signaling in cancer stemness and 
malignant behavior. Curr Opin Cell Biol 19, 150-158 (2007). 
78. Phelps, R.A., et al. A two-step model for colon adenoma initiation and 
progression caused by APC loss. Cell 137, 623-634 (2009). 
79. Vermeulen, L., et al. Wnt activity defines colon cancer stem cells and is regulated 
by the microenvironment. Nat Cell Biol 12, 468-476 (2010). 
80. Malbon, C.C. Beta-catenin, cancer, and G proteins: not just for frizzleds anymore. 
Sci STKE 2005, pe35 (2005). 
81. Kaiser, S., et al. Transcriptional recapitulation and subversion of embryonic colon 
development by mouse colon tumor models and human colon cancer. Genome 
biology 8, R131 (2007). 
82. Tothova, Z. & Gilliland, D.G. FoxO transcription factors and stem cell 
homeostasis: insights from the hematopoietic system. Cell stem cell 1, 140-152 
(2007). 
83. Pellicano, F., et al. FOXO transcription factor activity is partially retained in 
quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML 
progenitor cells. Blood (2009). 
84. Naka, K., et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells 
in chronic myeloid leukaemia. Nature 463, 676-680 (2010). 
85. Van der Flier, L.G., et al. The Intestinal Wnt/TCF Signature. Gastroenterology 
132, 628-632 (2007). 
 41
86. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Opinion: 
migrating cancer stem cells - an integrated concept of malignant tumour 
progression. Nat Rev Cancer 5, 744-749 (2005). 
87. Todaro, M., et al. Colon cancer stem cells dictate tumor growth and resist cell 
death by production of interleukin-4. Cell stem cell 1, 389-402 (2007). 
88. Varnat, F., et al. Human colon cancer epithelial cells harbour active 
HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, 
metastasis and stem cell survival and expansion. EMBO Mol Med 1, 338-351 
(2009). 
89. Jhawer, M., et al. PIK3CA mutation/PTEN expression status predicts response of 
colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. 
Cancer research 68, 1953-1961 (2008). 
90. Krol, J., et al. The transcription factor FOXO3a is a crucial cellular target of 
gefitinib (Iressa) in breast cancer cells. Molecular cancer therapeutics 6, 3169-
3179 (2007). 
91. Essafi, A., et al. Direct transcriptional regulation of Bim by FoxO3a mediates 
STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24, 2317-2329 
(2005). 
92. Kreso, A. & O'Brien, C.A. Colon cancer stem cells. Curr Protoc Stem Cell Biol 
Chapter 3, Unit 3 1 (2008). 
93. Cespedes, M.V., et al. Orthotopic microinjection of human colon cancer cells in 
nude mice induces tumor foci in all clinically relevant metastatic sites. Am J 
Pathol 170, 1077-1085 (2007). 
94. Barbachano, A., et al. SPROUTY-2 and E-cadherin regulate reciprocally and 
dictate colon cancer cell tumourigenicity. Oncogene 29, 4800-4813 (2010). 
95. Dignam, J.D., Lebovitz, R.M. & Roeder, R.G. Accurate transcription initiation by 
RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic 
acids research 11, 1475-1489 (1983). 
96. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative 
C(T) method. Nat Protoc 3, 1101-1108 (2008). 
97. Vandesompele, J., et al. Accurate normalization of real-time quantitative RT-PCR 
data by geometric averaging of multiple internal control genes. Genome Biol 3, 
RESEARCH0034 (2002). 
98. Devitt, G., Thomas, M., Klibanov, A.M., Pfeiffer, T. & Bosch, V. Optimized 
protocol for the large scale production of HIV pseudovirions by transient 
transfection of HEK293T cells with linear fully deacylated polyethylenimine. J 
Virol Methods 146, 298-304 (2007). 
99. Aguilar, S., et al. Bone marrow stem cells expressing keratinocyte growth factor 
via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. 
PLoS One 4, e8013 (2009). 
100. Barde, I., et al. Efficient control of gene expression in the hematopoietic system 
using a single Tet-on inducible lentiviral vector. Mol Ther 13, 382-390 (2006). 
101. Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt 
signaling pathway. PLoS One 5, e9370 (2010). 
 
 






